Objective To evaluate the effect of cryoprecipitate-based blood component therapy on reducing perioperative risk in patients treated with portaazygous devascularization and to assess its influence on risk of post-operative complications.Methods Sixty-eight patients with portal hypertension who were scheduled for portaazygous devascularization were randomly assigned to receive either the standard surgery (control group, n=34) or surgery combined with perioperative transfusion of 10U cryoprecipitate (treatment group, n=34) .Data recorded for inter-group comparative analysis (t-test) included postoperative blood loss, prothrombin time, and recovery time, as well as incidences of re-hemorrhage in the gastrointestinal tract and of portal vein thrombosis.Results Compared with the control group, the cryoprecipitate-transfused patients showed significantly lower amount of blood loss after surgery and significantly lower incidence of postoperative bleeding and of re-hemorrhage in the gastrointestinal tract.The cryoprecipitate-transfused patients also experienced a shorter duration recovery period, with less days of in-hospital stay.There was no increase in the incidence of portal vein thrombosis after the use of cryoprecipitate.Conclusion Application of cryoprecipitate during portaazygous devascularization surgery is safe and can improve coagulation function and reduce the risk of perioperative bleeding.Perioperative cryoprecipitate administration also benefits postoperative recovery and does not increase the incidence of portal vein thrombosis.